Dabrafenib Mesylate，又称甲磺酸达拉非尼，是可口服的B-raf (BRAF)抑制剂，作用于c-Raf和B-Raf V600E的IC₅₀分别为5 nM和0.6 nM，临床上用于治疗携带有BRAF-V600E突变的不可切除性黑色素瘤和转移性黑色素瘤。

参考文献

[1] Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. doi: 10.1158/1535-7163.MCT-11-0989(IF:4.856).

[2] Rheault TR, Stellwagen JC, Adjabeng GM, et al. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med Chem Lett. 2013 Feb 7;4(3):358-62. doi: 10.1021/ml4000063(IF:3.737).

-25~-15℃保存，有效期3年。